Nanomedicine approaches against SARS-CoV-2 and variants

J Control Release. 2024 Jan:365:101-111. doi: 10.1016/j.jconrel.2023.11.004. Epub 2023 Nov 22.


The world is grappling with the ongoing crisis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a global pandemic that continues to have a detrimental impact on public health and economies worldwide. The virus's relentless mutation has led to more transmissible, immune-evasive strains, thereby escalating the incidence of reinfection. This underscores the urgent need for highly effective and safe countermeasures against SARS-CoV-2 and its evolving variants. In the current context, nanomedicine presents an innovative and promising alternative to mitigate the impacts of this pandemic wave. It does so by harnessing the structural and functional properties at a nanoscale in a straightforward and adaptable manner. This review emphasizes the most recent progress in the development of nanovaccines, nanodecoys, and nanodisinfectants to tackle SARS-CoV-2 and its variants. Notably, the insights gained and strategies implemented in managing the ongoing pandemic may also offer invaluable guidance for the development of potent nanomedicines to combat future pandemics.

Keywords: Nanodecoy; Nanomedicine; Nanovaccine; SARS-CoV-2; Variants.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Humans
  • Nanomedicine
  • Pandemics / prevention & control
  • SARS-CoV-2*